Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 15/20 | 1.00 |
| ▸ | VDAC2 | P45880 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erastin SCHEMBL31385520 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| Erastin SCHEMBL4457820 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| Erastin SCHEMBL22213543 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL13633718 | 0.94 | SLC7A11 (0.89) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL1593568 | 0.94 | SLC7A11 (0.88) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL25793246 | 0.93 | SLC7A11 (0.87) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL5440840 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL14222558 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL4519119 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL4463410 | 0.91 | SLC7A11 (0.84) | SLC7A11VDAC2HIF1ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080133-A | Supermolecule polypeptide hydrogel with iron death reversal function and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-121550424-B | MEC nano probe, preparation method and application | The First Affiliated Hospital of Xiamen University (Xiamen First Hospital Xiamen Red Cross Hospital Xiamen diabetes Institute) (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122056889-A | Application of TLC69 as ARIH activating agent in preparation of medicine for treating triple negative breast cancer | 浙江大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4739299-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-122005493-A | Bioactive molecule delivery method based on probiotics exosomes | 东北林业大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260028590-A1 | FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS USING THEREOF | UNIV NAT CHENG KUNG (TW) | 2026-01-29 | — | — | US | claimed |
| EP-4561696-A1 | REVERSAL OF CELLULAR SENESCENCE BY TREATMENT WITH LOW FREQUENCY ULTRASOUND | Mechanobiologics, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| US-20250161297-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FSP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-22 | — | — | US | claimed |
| CN-120000798-A | Application of iron death inducer combined with anti-angiogenesis medicine in preparation of medicine for treating tumor | 浙江大学医学院附属第四医院 | 2025-05-16 | — | — | CN | claimed |
| WO-2022120187-A2 | METHOD OF DETERMINING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES | SHATTUCK LABS, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| EP-4008330-A1 | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-08 | — | — | EP | claimed |
| CN-114533760-A | Manganese-based nanoenzyme as iron death inhibitor and application thereof in liver injury | 华中农业大学 | 2022-05-27 | — | — | CN | claimed |
| EP-4000618-A1 | COMBINATION OF AT LEAST ONE INHIBITOR OF THE XC TRANSPORTER WITH AT LEAST ONE INHIBITOR OF MEMBRANE-BOUND CATALASE FOR INHIBITING AND / OR INACTIVATING TUMOR CELLS | Motz, Manfred (DE) | 2022-05-25 | — | — | EP | claimed |
| CN-114504655-A | Drug-loaded microsphere for targeted inhibition of TNBC cell activity, preparation method and application thereof | 川北医学院附属医院 | 2022-05-17 | — | — | CN | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114366811-A | Bionic nano motor for targeted drug delivery and preparation method and application thereof | 核工业四一六医院 | 2022-04-19 | — | — | CN | claimed |
| EP-3355923-B1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN THE TREATMENT OF DRUG RESISTANT MELANOMA | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-02-23 | — | — | EP | claimed |
| CN-114028404-A | Application of orychophragmine D in preparation of medicine for inhibiting small intestine crypt epithelial cell iron death | 中国人民解放军军事科学院军事医学研究院 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028590-A1 | FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS USING THEREOF | AIFM2, PLIN5, ENTPD5 | SLC7A11 68/4885VDAC2 711/4885HIF1A 642/4885 |
| US-20250161297-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FSP1 | CYFIP1, FNIP1, PFN1 | SLC7A11 4035/4885VDAC2 3471/4885HIF1A 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.